Core Insights - Nexalin Technology, Inc. has received a U.S. Design Patent for its HALO™ Clarity neuromodulation device, providing 15 years of design protection, which enhances its intellectual property portfolio [1][5] Group 1: Product Overview - HALO™ Clarity is a non-invasive neuromodulation device aimed at treating mental health and neurological conditions, including Alzheimer's, without the need for pharmaceuticals or surgery [2][3] - The device is designed for at-home use under professional supervision, allowing remote monitoring and guidance from physicians, which can improve patient access and reduce healthcare costs [3][8] Group 2: Clinical Development - Nexalin is conducting multiple clinical studies for HALO™ Clarity targeting conditions such as anxiety, insomnia, PTSD, and mild traumatic brain injury, with positive feedback from the FDA on pivotal trial designs [4] - The DIFS™ platform has been involved in over two dozen trials globally, showing consistent safety and efficacy signals [4] Group 3: Advantages of HALO™ Clarity - The device offers enhanced convenience by allowing therapy at home, reducing the need for frequent office visits [8] - It enables remote clinician oversight, allowing real-time data review and protocol adjustments through telemedicine [8] - The system may improve treatment compliance and continuity while potentially lowering overall care costs by minimizing in-clinic resource requirements [8]

Core Viewpoint - Nexalin Technology, Inc. has successfully enrolled the first patients in a clinical trial for its Deep Intracranial Frequency Stimulation (DIFS™) technology, aiming to treat mild traumatic brain injury (mTBI) and post-traumatic stress disorder (PTSD) [1][2][3] Company Overview - Nexalin Technology focuses on developing innovative neurostimulation products to address the global mental health crisis, utilizing non-invasive bioelectronic medical technology [5] - The company's DIFS™ technology is designed to penetrate deep brain structures associated with mental health disorders, potentially offering enhanced patient responses without adverse side effects [5] Clinical Trial Details - The clinical trial is being conducted in collaboration with the University of California, San Diego (UCSD) and the VA San Diego Healthcare System, marking a significant step in evaluating the efficacy of Nexalin's HALO™ Clarity devices [2][3] - The trial aims to gather comprehensive data on the impact of DIFS™ technology on mental health conditions, particularly for underserved populations such as veterans [3][4] Technology and Devices - The HALO™ Clarity device is currently under evaluation and is not yet approved for marketing in the U.S., with its safety and efficacy still being assessed by the FDA [6] - Nexalin's HALO™ Clarity devices provide non-invasive, at-home neurostimulation therapy, integrated with AI for remote monitoring of patient adherence and treatment progress [4]